Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...
Gilead reports updated data from trial of acclaimed HIV PrEP drug
Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...
Inquirer on MSN12d
Gilead licenses HIV-prevention drug to generic drugmakers
US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell ...
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...
CSR Wire6d
Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV Epidemic
Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...
FiercePharma13d
Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV PrEP med
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...
manilatimes on MSN13d
Gilead licenses anti-HIV drug to generic drugmakers
United States pharmaceutical giant Gilead said on Wednesday it had signed licensing deals with six generic drugmakers to ...
BioSpace13d
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...
Managed Healthcare Executive11d
Gilead to Distribute Lenacapavir in Top HIV Countries, Critics Unhappy
The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by ...
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir ...
Gilead's tie up with generic cos may not address HIV challenge
Gilead's partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too ...